Ayurcann Holdings (AYURF) Fair Value & Analysis
Healthcare · US · Market cap $389K
Ayurcann Holdings
AYURF · US
Fair value as of: Jun 26, 2026
From 7 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.1100 to $0.0020 (−98.2%) since Jun 24, 2026. Share price +5.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0019 – $0.0324 · fair‑value band $0.0020 – $0.0020 · the $0.0020 price screens above the $0.0020 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Ayurcann Holdings (AYURF) currently trades at $0.0020, while our model-based Fair Value estimate is $0.0020 — implying the stock looks roughly 0.2% overvalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Ayurcann Holdings generated revenue of $31.3M at a net margin of -13.9%. Revenue grew 2.1% year over year. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. The company offers extraction, processing, and co-manufacturing of pharma grade cannabis to produce various derivative cannabis products in the medical and recreational markets. It also manufactures and distributes cannabis products. The company sells product under the Fuego, H&S, and XPLOR brand names. Ayurcann Holdings Corp. is headquartered in Pickering, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ayurcann Holdings reported revenue of $31.1M in FY2025 versus $7.6M in FY2021, a compound +42.1%/yr. Reported net income was −$3.5M in FY2025.
Is AYURF fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ayurcann Holdings (AYURF) undervalued?
What is the fair value of AYURF?
What is the quality score of AYURF?
What is the revenue of Ayurcann Holdings (AYURF)?
What is the net profit margin of AYURF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.